Pulse Biosciences (NASDAQ:PLSE) Price Target Raised to $43.00

Pulse Biosciences (NASDAQ:PLSE) had its price objective boosted by Canaccord Genuity Group from $32.00 to $43.00 in a research note released on Monday, MarketBeat.com reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Friday, July 17th. Oppenheimer restated an “outperform” rating on shares of Pulse Biosciences in a research note on Tuesday, July 28th. Finally, Wall Street Zen downgraded Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $41.00.

Pulse Biosciences Price Performance

PLSE opened at $43.32 on Monday. The company has a market capitalization of $3.00 billion, a price-to-earnings ratio of -36.71 and a beta of 1.61. The firm’s fifty day moving average price is $30.12 and its two-hundred day moving average price is $24.32. Pulse Biosciences has a 1 year low of $12.56 and a 1 year high of $45.90.

Pulse Biosciences (NASDAQ:PLSE) last posted its earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.29) by ($0.07). Pulse Biosciences had a negative return on equity of 100.22% and a negative net margin of 6,755.78%.The firm had revenue of $0.43 million during the quarter, compared to the consensus estimate of $0.53 million. As a group, equities analysts anticipate that Pulse Biosciences will post -1.29 EPS for the current year.

Hedge Funds Weigh In On Pulse Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PLSE. BlackRock Inc. purchased a new position in Pulse Biosciences in the 2nd quarter valued at approximately $40,672,000. Portolan Capital Management LLC bought a new stake in Pulse Biosciences during the 3rd quarter valued at $1,809,000. Brooklyn Investment Group lifted its position in shares of Pulse Biosciences by 330.7% during the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after acquiring an additional 100,081 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Pulse Biosciences by 8.2% in the first quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock worth $18,698,000 after acquiring an additional 65,884 shares during the period. Finally, Bank of New York Mellon Corp bought a new position in shares of Pulse Biosciences in the second quarter worth $1,196,000. Institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.